1 |
Zhuang Q, Huang S, Li Z. Prospective role of 3βHSD1 in prostate cancer precision medicine. Prostate 2023. [PMID: 36842160 DOI: 10.1002/pros.24504] [Reference Citation Analysis]
|
2 |
Mei Z, Yang T, Liu Y, Gao Y, Hou Z, Zhuang Q, He D, Zhang X, Tan Q, Zhu X, Qin Y, Chen X, Xu C, Bian C, Wang X, Wang C, Wu D, Huang S, Li Z. Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment. Cell Rep Med 2022;3:100608. [PMID: 35584629 DOI: 10.1016/j.xcrm.2022.100608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
3 |
Hou Z, Huang S, Mei Z, Chen L, Guo J, Gao Y, Zhuang Q, Zhang X, Tan Q, Yang T, Liu Y, Chi Y, Qi L, Jiang T, Shao X, Wu Y, Xu X, Qin J, Ren R, Tang H, Wu D, Li Z. Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. Cell Rep Med 2022;3:100561. [PMID: 35492874 DOI: 10.1016/j.xcrm.2022.100561] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
4 |
Hou Z, Huang S, Li Z. Androgens in prostate cancer: A tale that never ends. Cancer Lett 2021;516:1-12. [PMID: 34052327 DOI: 10.1016/j.canlet.2021.04.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
|